The objectives of this study were (i) to report the area and distribution of RCNP at baseline and 100 weeks using UWFA in a large prospective patient cohort, (ii) to report progression of peripheral and posterior pole (>10 DA) RCNP while on concomitant anti-VEGF treatment for macular oedema, (iii) identify associated risk factors for conversion and (iv) suggest clinically useful management guidance. Here, VEGFA is linked to macular retinal edema.